FT: AstraZeneca investors turn up the heat under CEO Brennan

The Financial Times has been taking the temperature of some of AstraZeneca's ($AZN) biggest investors, and the newspaper reports that it's reaching feverish proportions as CEO David Brennan continues to reject calls for some sizable acquisitions and deal-making. "The chief executive is under intense pressure," says one investor, as speculation begins to ramp up over when Brennan may step down and who would step in. Some analysts, meanwhile, have delivered a scathing assessment of the company's lackluster response to generic competition and R&D setbacks. For some, desperate times demand desperate actions. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.